Background: We report results of a multicenter clinical experience study examining
| INTRODUCTION
When managing thyroid nodules physicians need to distinguish potentially malignant nodules from those with benign disease to limit unnecessary surgery. Ultrasound imaging followed by cytopathology review of fine needle aspirations (FNA) is the current standard of care for the diagnosis of thyroid nodule malignancy. Although cytopathology categorizes the majority of nodules as benign or malignant with a high degree of certainty, up to 30% of nodules are reported as indeterminate, where the presence of malignancy is less certain. [1] [2] [3] [4] Only 12%-20% of surgically resected indeterminate nodules that have atypia of undetermined significance or a follicular lesion of undetermined significance (AUS/FLUS, Bethesda category III) diagnosis will have malignancy. 5 The malignancy rate only increases to 25%-33% in nodules that are a follicular neoplasm or are suspicious for follicular neoplasm (FN/SFN, Bethesda category IV). 5 Rates of malignancy in
Bethesda category III and IV nodules are likely even lower when nodules that undergo observation rather than surgery are also considered. Regardless, indeterminate cytopathology often triggers unnecessary diagnostic lobectomy and even total thyroidectomy, given concern for cancer.
Molecular testing of nodules with indeterminate cytology diagnosis following a thyroid nodule FNA has been incorporated into routine care to help resolve diagnostic uncertainty. 6 While mutations strongly associated with malignancy, such as BRAF V600E, RET fusions, and TERT can assist in surgical decision making, other mutations considered weak drivers of cancer carry less certainty. [7] [8] [9] [10] RAS mutations, the most common type in thyroid nodules, have been reported to have variable positive and negative predictive value for malignancy, often occurring in benign nodules. [11] [12] [13] [14] [15] Furthermore, residual risk of malignancy (5%-25%) is present in patients who lack any detectable mutational change. 16, 17 Multiple studies have described the ability of RNA-based risk classifiers to help resolve diagnostic uncertainty in indeterminate thyroid nodules. [18] [19] [20] A messenger RNA risk classifier can help to rule out the need for surgery in indeterminate nodules due to its high negative predictive value for malignancy. 19, 20 However, its less than optimal positive predictive value limits the ability to rule in the need for sur- (RET/PTC1), and CCDC6/RET (RET/PTC3) rearrangements as previously described. 18 microRNA expression analysis was performed by reverse transcription quantitative PCR for miR-29b-1-5p, miR-31-5p, miR-138-1-3p, miR-139-5p, miR-146b-5p, miR-155, miR-204-5p, miR-222-3p, miR-375, and miR-551b-3p as previously described. 18 MPT results were abstracted from patient medical reports and categorized as positive or negative using two approaches. The first approach was as previously described, 18 
| Statistical analysis
Statistical analysis was performed using R statistical software (r-project. org). P-values <.05 were considered statistically significant. Malignancyfree and surgery-free survival was calculated from the date of molecular testing using Kaplan-Meier survival analysis. A univariate and multivariate Cox proportional hazards regression model was used to assess the relationship between the independent clinical factors and MPT results compared to surgical treatment decisions and patient outcomes. The log rank test was used to compare the survival curves when appropriate.
The expected absolute risk of undergoing surgery over a range of pretest surgery probabilities was calculated for MPT results using rates observed in the study cohort and Bayes theorem. The probability of a negative MPT result (ie, the rate of negative test results) was calculated based on the performance characteristics of the test in the study cohort over a range of various baseline malignancy rates. 22 patients.
| RESULTS
Baseline and follow-up characteristics of the study cohort are shown in Table 1 Abbreviations: MPT, multiplatform mutation and microRNA test; mos, months; yrs, years; cm, centimeters; min, minimum; max, maximum.
2 months. More than half of the cohort (55%) had clinical follow-up of at least 3 months and up to 2 years (median 9 months).
Over the 2-year follow-up period, we examined the probability at which patients underwent surgical treatment (diagnostic lobectomy or total thyroidectomy) for their thyroid nodules based on a positive or negative MPT result. Patients with a negative MPT result had a high probability of survival without undergoing a diagnostic lobectomy (81%) or total thyroidectomy (85%) surgery at 2 years follow-up ( Figure 1A,B) . Comparatively, patients with a positive result were at higher risk of undergoing lobectomy (HR 4.3, 95%CI 2.3-8.0, P = .0001) and even more so total thyroidectomy (HR 12.2, 95%CI
5.6-26.8, P < .0001).
In univariate analysis, a positive MPT result (HR 7.94, 95% CI 4.93-12.78, P < .0001) and to a lesser extent patient age (HR 0.98, 95%CI 0.96-0.99, P = .0007) were the only significant risk factors for any type of surgical treatment (diagnostic lobectomy or total thyroidectomy; Table S1 ). In multivariate analysis, a positive MPT result remained a predictive risk factor for surgical treatment (HR 9.1, 95%
CI 5.4-15.2, P < .0001; Table S1 ). Both patient age (HR 0.98, 95%CI
0.96-0.98, P = .0103) and nodule size (HR 1.03, 95%CI 1.01-1.05, P = .0017) were also predictive risk factors for surgical treatment, but to a lesser extent than positive MPT results.
Given that our study cohort was enriched for surgical events, we examined the expected rate of surgery in patients with positive or negative MPT results over various baseline rates of surgery (Supplemental Figure 1) . At a 24% surgery rate, which is the overall rate of surgery observed in the study, only 11% of patients with a negative MPT result were expected to undergo any type of surgical treatment (diagnostic lobectomy or total thyroidectomy) for their thyroid nodule.
Comparatively, 84% of those with a positive result were expected to undergo surgical treatment.
In addition to determining the impact of MPT results on surgical decisions, we examined whether those decisions were aligned with patient outcome. Over the 2 year follow-up period, 14% (26/180) of patients had a surgical pathology determined malignant outcome with a 2 month average time to diagnosis of malignancy after MPT testing.
Patients with a negative MPT result had a high probability (92%) of survival without malignancy for up to 2 years follow-up ( Figure 2 ).
Comparatively, patients with a positive MPT result had a low probability (43%) of survival without malignancy and were at significantly Incorporation of microRNA testing of nodules with weak driver mutations into MPT significantly improved the rate of a negative MPT result from 69% (124/180) to 87% (156/180) in the study cohort. This improvement was consistent over various baseline rates of malignancy examined (Figure 3 ). When MPT included microRNA analysis of nodules with weak drivers, an 87% probability of malignancy-free survival was observed for a negative diagnosis, and this carried no statistically different cancer risk than a negative MPT result without weak driver testing (87% vs 92%, P = .247). Positive results confirmed a low probability of malignancy-free survival in the secondary analysis (38%), similar to the primary analysis (43%; 38% vs 43%, P = .363).
| DISCUSSION
We performed a multicenter clinical experience study of Bethesda III and IV category nodules that underwent past clinical MPT testing to evaluate the impact of test results on future real-world decisions to surgically treat indeterminate thyroid nodules. We also examined the risk of malignancy conferred by test results over time. Over the 2-year follow-up period, patients with a negative MPT result had a high probability of survival without undergoing a diagnostic lobectomy or total thyroidectomy and had a high probability of survival without malignancy. MPT positive results placed patients at higher risk of undergoing diagnostic lobectomy and even more so total thyroidectomy. A positive result was an independent risk factor for surgical treatment of nodules and the only risk factor for malignancy.
The rate of surgical treatment for indeterminate thyroid nodules that underwent MPT testing was only 24% when all patients in our study were considered. Surgery rates were artificially high at 45% in the study cohort, which was enriched for a higher number of patients who had surgical records compared to those who had existing clinical follow-up records. A surgical treatment rate of 24%, as observed in our study, is in line with the rate required for a molecular test to be cost effective for the preoperative management of indeterminate thyroid nodules. 23 Furthermore, the expected rate of surgery (11%) for a negative MPT diagnoses was consistent with the rate previously reported for benign cytology (Bethesda category II), supporting the utility of MPT as a rule out test. 24 Our results also show that other risk factors for surgical treatment, such as nodule size and patient age, can also influence surgical decisions in such cases.
The performance of molecular tests for thyroid nodules has often been reported at a malignancy prevalence ranging from 24% to 32%, as most studies have only included patients who have undergone surgical treatment. [18] [19] [20] 25 The rate of malignancy in our study cohort was only 14%, which is expected in a cohort of Bethesda category III and IV nodules that include patients who underwent conservative clinical follow up rather than surgery. Even at this lower rate of malignancy, patients with an MPT positive result only had a 43% probability of cancer-free survival. In other words, patients with a positive MPT result had a 57% probability of malignancy, which F I G U R E 2 Kaplan Meier analysis for probability of survival without malignancy based on multiplatform mutation and microRNA (MPT) negative (green) or positive (red) results. Compared to patients with an MPT negative result, patients with an MPT positive result were at higher risk of malignancy by hazard ratio (HR) analysis. Abbreviation: CI, confidence interval F I G U R E 3 Sensitivity analysis for the expected rate of a negative multiplatform mutation and microRNA test (MPT) result based on incorporation of microRNA analysis of nodules with weak driver mutations (green solid line) into MPT or the lack there of (green dashed line) over various baseline rates of malignancy. Dotted lines represent 95% confidence intervals [Color figure can be viewed at wileyonlinelibrary.com] supports the ability of a positive result to rule in the need for surgery. This probability is also similar to that which has been projected in a previous clinical validation study of MPT at a 14% malignancy prevalence. 18 An MPT positive result placed patients at 13 times higher risk of malignancy compared to those with an MPT negative result, which carried a high probability (92%) of cancer-free survival over 2 years follow-up. This high probability of cancer-free survival for negative results is consistent with a test that effectively rules out the need for surgery.
In our study, we examined the impact of reflex microRNA testing not only when nodules lacked mutations but also when nodules had weak driver mutations, given their association with both benign and malignant disease. One impediment, we experienced in our study was the unavailability of clinical follow-up records for some patients who underwent observation rather than surgery, which enriched our study cohort for patients who had surgical treatment for their nodule. This limitation is expected in real life clinical experience studies where patients with a negative molecular result are managed conservatively. This lack of records also reduced the rate of negative MPT results in the study cohort, given that most patients (93%) who were lost to follow up had a negative MPT result. Consistently, 80% of all patients (n = 337) in the study had negative MPT results compared to 69% in our study cohort (n = 180). In addition, patients who underwent clinical followup only had a median follow-up time of 9 months. Although the median time to diagnosis of malignancy was less than this (2 months),
we cannot exclude the possibility that additional malignancies occurred after the minimum 3 month clinical follow-up period. Furthermore, there were only a limited number of malignant cases in our study (n = 26).
Our multicenter clinical experience study supports results of others who have reported high positive and negative predictive value for MPT testing of indeterminate thyroid nodules. 18 In our 
AUTHOR CONTRIBUTIONS
JWS, AS, MF, RHB, JT, NF, PG, RG, and EG each participated in generating data for the study, reviewed data analysis and manuscript drafts, and approved the final draft of the manuscript.
